Revolutionizing the treatment of chronic disease.
Leveraging our NanoPortal™ technology, we are developing a portfolio of highly differentiated products comprised of miniature, sub-dermal drug implants.
Our Pipeline
exenatide
proprietary compound
(Non-Alcoholic Steatohepatitis)
proprietary compound
exenatide
exenatide
proprietary compound
(Non-Alcoholic Steatohepatitis)
proprietary compound
exenatide
exenatide
proprietary compound
(Non-Alcoholic Steatohepatitis)
proprietary compound
exenatide
Overview
A miniature, GLP-1 agonist implant designed to address medication non-adherence and improve tolerability.
Built with our NanoPortal™ technology, NPM-119 is designed to provide steady, long-term therapeutic delivery of exenatide for at least six months.
By assuring medication adherence, NPM-119 may free patients with type 2 diabetes from burdens associated with oral and injectable medications, as well as provide confidence to physicians, caregivers and loved ones that patients are receiving the intended therapeutic benefits from their medicine.
Target
Under investigation for the treatment of type 2 diabetes and obesity.
Medication non-adherence affects an alarming number of patients – approximately 50%
Development
Phase 2 clinical trial.
In 2023, we intend to file an Investigational New Drug application with the U.S. FDA to support the initiation of a Phase 2 clinical study of NPM-119 called LIBERATE-1.
LIBERATE-1 is the first clinical study investigating the effects of NPM-119 in patients with type 2 diabetes and of our platform NanoPortal implant technology.